extra_costs_ques

extra_costs_ques - UNIVERSITY OF CALIFORNIA HAAS SCHOOL OF...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
UNIVERSITY OF CALIFORNIA HAAS SCHOOL OF BUSINESS EWMBA 201A—Economic Analysis for Business Decisions Fall 2007 Professor Catherine Wolfram Question 1 Advagen is a pharmaceutical company with a new topical skin cream product. Advagen’s hope for this product, currently called compound Alpha, was that it would be the first prescription strength pharmaceutical product to treat skin wrinkles and that it would appeal to a huge anti-aging market as a “cosme-ceutical.” In line with this, Advagen has spent $4 million so far on clinical trials and the FDA approval of compound Alpha. Alas, the FDA has rejected Advagen’s claim that compound Alpha can be used for treating wrinkles, and has only approved it for a more limited set of skin conditions, such as eczema. Advagen had planned a $6 million advertising campaign for the rollout of compound Alpha, made up of $2 million targeted towards doctors and $4 million for broad consumer advertising. The consumer advertising will not be useful if compound Alpha can be prescribed only for specific skin conditions, but the doctor-
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 09/21/2009 for the course EWMBA 201A taught by Professor Wolfram during the Fall '07 term at Berkeley.

Page1 / 3

extra_costs_ques - UNIVERSITY OF CALIFORNIA HAAS SCHOOL OF...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online